Integra LifeSciences (NASDAQ:IART) Updates FY 2025 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 2.410-2.510 for the period, compared to the consensus earnings per share estimate of 2.510. The company issued revenue guidance of $1.7 billion-$1.7 billion, compared to the consensus revenue estimate of $1.7 billion. Integra LifeSciences also updated its FY25 guidance to $2.41 to $2.51 EPS.

Analyst Ratings Changes

A number of research analysts have issued reports on IART shares. Morgan Stanley initiated coverage on Integra LifeSciences in a report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price target for the company. Citigroup increased their price target on shares of Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a report on Tuesday, November 5th. Three analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $23.00.

Integra LifeSciences Price Performance

Shares of NASDAQ:IART traded up $2.31 during midday trading on Tuesday, reaching $24.36. 202,650 shares of the company’s stock traded hands, compared to its average volume of 551,138. The company has a fifty day simple moving average of $23.68 and a two-hundred day simple moving average of $21.81. Integra LifeSciences has a 1 year low of $16.81 and a 1 year high of $44.91. The company has a market cap of $1.88 billion, a P/E ratio of -269.58, a PEG ratio of 0.73 and a beta of 1.17. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Integra LifeSciences (NASDAQ:IART) last posted its quarterly earnings data on Tuesday, February 25th. The life sciences company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.86 by $0.11. The business had revenue of $442.65 million for the quarter, compared to the consensus estimate of $445.15 million. Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company’s revenue was up 11.5% compared to the same quarter last year. During the same period last year, the firm posted $0.89 earnings per share. Equities analysts predict that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Insider Buying and Selling

In other news, EVP Michael J. Mcbreen sold 1,700 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total value of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares in the company, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 3.10% of the stock is currently owned by insiders.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.